Shopping Cart 0
Cart Subtotal
USD 0

Ocular Therapeutix Inc (OCUL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Ocular Therapeutix Inc (Ocular), formerly I-Therapeutix Inc is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for diseases using hydrogel platform technology. The company's products include DEXTENZA, sustained release travoprost and posterior segment injections. Its hydrogel technology uses polyethylene glycol to create ophthalmic sustained drug delivery systems. Ocular's hydrogel provides containment, localization and protection from inflammatory response, and a material for sustained delivery of drugs to the eye. The company also provides ReSure Sealant, a ocular sealant proven in clinical trial to be safe in sealing clear corneal incisions following cataract surgery. Its products are used for the treatment of glaucoma and ocular hypertension, post-operative inflammation, allergic conjunctivitis, dry eye and retinal diseases. Ocular is headquartered in Bedford, Massachusetts, the US.

Ocular Therapeutix Inc (OCUL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Ocular Therapeutix Inc, Medical Devices Deals, 2012 to YTD 2018 10

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Ocular Therapeutix Raises USD 8.5 Million In Series E Venture Financing 12

Ocular Therapeutix Raises USD 24 Million In Extended Series D Financing 13

Partnerships 15

Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 15

Equity Offering 17

Ocular Therapeutix Raises USD37.3 Million in Public Offering of Shares 17

Ocular Therapeutix Prices Public Offering of Shares for USD25 Million 19

Ocular Therapeutix Raises USD101.2 Million in Public Offering of Shares 21

Ocular Therapeutix Completes Exercise of Underwriter's Over Allotment Option for IPO for USD75 Million 23

Ocular Therapeutix Inc-Key Competitors 25

Ocular Therapeutix Inc-Key Employees 26

Ocular Therapeutix Inc-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 28

Financial Announcements 28

Aug 07, 2018: Ocular Therapeutix announces second quarter 2018 financial results 28

Mar 08, 2018: Ocular Therapeutix Reports Fourth Quarter and Year End 2017 Financial Results and Business Update 29

Nov 07, 2017: Ocular Therapeutix Reports Third Quarter 2017 Financial Results and Provides Corporate Update 31

Aug 08, 2017: Ocular Therapeutix Reports Second Quarter 2017 Financial Results and Provides Corporate Update 33

Aug 03, 2017: Ocular Therapeutix Appoints Daniel Bollag, Ph.D., as Senior Vice President, Regulatory Affairs, Pharmacovigilance and Quality 35

Aug 01, 2017: Ocular Therapeutix Announces Antony Mattessich Assumes Role as Chief Executive Officer 36

May 05, 2017: Ocular Therapeutix Reports First Quarter 2017 Financial Results 37

Corporate Communications 39

Sep 08, 2017: Ocular Therapeutix Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical Officer 39

Jun 26, 2017: Ocular Therapeutix Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 40

Jun 22, 2017: Ocular Therapeutix Announces Executive Transition Plans 41

Apr 06, 2017: Ocular Therapeutix Appoints George Migausky as Interim Chief Financial Officer 42

Mar 10, 2017: Ocular Therapeutix Reports Fourth Quarter and Full Year 2016 Financial Results 43

Product News 45

12/22/2017: Ocular Therapeutix Provides Legal Update 45

05/02/2017: Ocular Therapeutix Announces Data on OTX-TKI at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 46

01/08/2018: Ocular Therapeutix Announces Kevin Hanley as Senior Vice President, Technical Operations and Naymisha Patel as Vice President of Quality 47

Product Approvals 48

Jul 12, 2017: OCULAR THERAPEUTIX INVESTOR ALERT: Legal Investigation Continues After FDA Denies Dextenza New Drug Application 48

Jul 11, 2017: Ocular Therapeutix Receives Complete Response Letter from FDA for DEXTENZA NDA 49

Jul 10, 2017: Ocular Therapeutix Submits Amendment to Potentially Extend Review for DEXTENZA New Drug Application 50

Feb 22, 2017: Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for DEXTENZA for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery 51

Jan 23, 2017: Ocular Therapeutix Resubmits NDA for DEXTENZA for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery 52

Clinical Trials 53

Apr 09, 2018: Ocular Therapeutix to Present Data at the American Society of Cataract and Refractive Surgery Symposium 53

May 11, 2017: Ocular Therapeutix Presented Phase 3 Data for DEXTENZA at the Association for Research in Vision and Ophthalmology Annual Meeting 54

May 09, 2017: Ocular Therapeutix Presents Preclinical Data on Pharmacokinetics, Efficacy and Tolerability of Sustained Release Intravitreal Tyrosine Kinase Inhibitor Hydrogel Depot (OTX-TKI) at the ARVO Annual Meeting 56

May 08, 2017: Ocular Therapeutix Presents Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium 58

May 02, 2017: Ocular Therapeutix to Present Data on DEXTENZA at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 59

May 02, 2017: Ocular Therapeutix to Present Data on OTX-TP (travoprost insert) at the Association for Research in Vision and Ophthalmology Annual Meeting 60

Apr 24, 2017: Ocular Therapeutix to Present Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium 61

Mar 15, 2017: New Publication Describes Positive Patient Experience in Study of Ocular Therapeutix DEXTENZA Following Cataract Surgery 63

Jan 04, 2017: Ocular Therapeutix Announces Additional Successful Results for Phase 3 Clinical Trial of DEXTENZA 64

Appendix 65

Methodology 65

About GlobalData 65

Contact Us 65

Disclaimer 65


List Of Figure

List of Figures

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Ocular Therapeutix Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ocular Therapeutix Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Ocular Therapeutix Inc, Medical Devices Deals, 2012 to YTD 2018 10

Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Ocular Therapeutix Raises USD 8.5 Million In Series E Venture Financing 12

Ocular Therapeutix Raises USD 24 Million In Extended Series D Financing 13

Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 15

Ocular Therapeutix Raises USD37.3 Million in Public Offering of Shares 17

Ocular Therapeutix Prices Public Offering of Shares for USD25 Million 19

Ocular Therapeutix Raises USD101.2 Million in Public Offering of Shares 21

Ocular Therapeutix Completes Exercise of Underwriter's Over Allotment Option for IPO for USD75 Million 23

Ocular Therapeutix Inc, Key Competitors 25

Ocular Therapeutix Inc, Key Employees 26

Ocular Therapeutix Inc, Other Locations 27

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Ocular Therapeutix Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.